[Prophylaxis of superficial bladder cancer with 1 mg of intravesical BCG: comparison with other doses].
Presentation of results obtained in 171 evaluable patients from a series of 181, presenting surface vesical cancer in Tis, Ta and T1 stages, treated with 3 different dosages of endovesical BCG as prophylaxis for tumour relapse: a) high dose, 100 to 120 mg, 72 patients; b) intermediate dose, 20 to 50 mg, 39 patients; and, c) minidose of 1 mg, 60 patients. Complications and adverse reactions were seen to be dose-dependent, also percentage of patients free of disease both after treatment and following addition of retreatment in several patients was similar in all the dosages used. It is thus concluded that endovesical BCG 1 mg, would be an optimal dosage for the prophylaxis of surface vesical cancer relapse.
Corti Ortíz
D
D
Servicio de Urología, Hospital Valdivia, Universidad Austral.
Rivera Garay
P
P
Avilés Jasse
J
J
Hidalgo Carmona
F
F
MacMillan Soto
G
G
Coz Cañas
L F
LF
Vargas Delaunoy
R
R
Susaeta Saénz de San Pedro
R
R
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000517:prevention & control*
D001500:BCG Vaccine
Profilaxis del cáncer vesical superficial con 1 mg de BCG endovesical: comparacion con otras dosis.